Lakefront Biotherapeutics NV current report, Q1 FY2026

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of January 2026. The filing serves to incorporate by reference a press release dated January 5, 2026 (Exhibit 99.1), into the company's existing Registration Statements on Form S-8.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or earnings report.

Material Changes

No material financial changes versus a prior comparable period are detailed in this filing text. The document solely references the issuance of a press release.

Guidance, Outlook, and Risks

The filing text does not provide specific guidance, outlook, management commentary, risks, or contingencies. It notes that the press release (Exhibit 99.1) contains a quote by Henry Gosebruch, but the content of that quote is not included in the provided text.

Investor Verification Checklist

  • Verify the actual content of the press release attached as Exhibit 99.1, as the summary text only references its existence.
  • Confirm the identity of the registrant as Galapagos NV, noting the discrepancy with the metadata company name.
  • Review the specific details of the January 5, 2026 announcement to understand the material event triggering this filing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.